We are live on ! Find out more
BKYI

BIO-key International
BKYI

7 hedge funds and large institutions have $14.3K invested in BIO-key International in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

17% more funds holding

Funds holding: 6 → 7 (+1)

0.69% less ownership

Funds ownership: 0.73% → 0.04% (-0.69%)

93% less capital invested

Capital invested by funds: $219K → $14.3K (-$204K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
7
Holders Change
+1
Holders Change %
+16.67%
% of All Funds
0%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$890
2
JP Morgan Chase
JP Morgan Chase
New York
+$485

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$196K
2
TRCT
Tower Research Capital (TRC)
New York
-$2.91K

BKYI Hedge Fund Activity: Q1 2024 in Review

7 institutional investors reported a position in BIO-key International (BKYI) for Q1 2024, worth a combined $14.3K — down 93% from $219K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new BKYI positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $890. The largest seller was Armistice Capital, exiting entirely with an estimated $196K sold.

  • 7 institutional investors held BIO-key International (BKYI) as of Q1 2024, up from 6 in Q4 2023.
  • Funds reported $14.3K of BIO-key International stock for Q1 2024, down 93% quarter-over-quarter.
  • 2 funds opened new BIO-key International positions in Q1 2024 and 1 closed out, a net change of +1 holder.
  • The largest BIO-key International buyer in Q1 2024 was UBS Group, an estimated $890 added.
  • The largest BIO-key International seller in Q1 2024 was Armistice Capital, an estimated $196K sold.

Based on aggregated 13F filings for Q1 2024.